Targeted therapy for neuromyelitis optica spectrum disorders
Neuromyelitis optica spectrum disorders (NMOSDs) have the characteristics of high relapse rate and high disability rate. The neurological deficits would become more and more serious with increasing relapse. Using corticosteroids pulse therapy, intravenous immunoglobulin or plasma exchange to reduce...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tianjin Huanhu Hospital
2020-10-01
|
| Series: | Chinese Journal of Contemporary Neurology and Neurosurgery |
| Subjects: | |
| Online Access: | http://www.cjcnn.org/index.php/cjcnn/article/view/2217 |
| _version_ | 1818300483647832064 |
|---|---|
| author | Yang⁃tai GUAN |
| author_facet | Yang⁃tai GUAN |
| author_sort | Yang⁃tai GUAN |
| collection | DOAJ |
| description | Neuromyelitis optica spectrum disorders (NMOSDs) have the characteristics of high relapse rate and high disability rate. The neurological deficits would become more and more serious with increasing relapse. Using corticosteroids pulse therapy, intravenous immunoglobulin or plasma exchange to reduce inflammation and inhibit neurological dysfunction is the main treatment principle of NMOSDs in the acute phase; drugs to prevent relapse of NMOSDs are mainly immunosuppressants, such as azathioprine, and targeted agents, such as CD19 monoclonal antibody, C5 complement, interleukin⁃6⁃receptor targeted antibodies and a proliferation⁃inducing ligand (APRIL)/transmembrance activator and calcium⁃modulator and cyclophilin ligand interactor (TACI) targeted therapy. Some targeted agents have been approved for clinical use. This article intended to review the targeted agents for NMOSDs patients for the purpose of improving the understanding of therapeutic strategies of NMOSDs.
DOI: 10.3969/j.issn.1672-6731.2020.10.001 |
| first_indexed | 2024-12-13T05:07:50Z |
| format | Article |
| id | doaj.art-db49a22f44a24ea984392449bb988f3d |
| institution | Directory Open Access Journal |
| issn | 1672-6731 |
| language | English |
| last_indexed | 2024-12-13T05:07:50Z |
| publishDate | 2020-10-01 |
| publisher | Tianjin Huanhu Hospital |
| record_format | Article |
| series | Chinese Journal of Contemporary Neurology and Neurosurgery |
| spelling | doaj.art-db49a22f44a24ea984392449bb988f3d2022-12-21T23:58:38ZengTianjin Huanhu HospitalChinese Journal of Contemporary Neurology and Neurosurgery1672-67312020-10-0120108438472172Targeted therapy for neuromyelitis optica spectrum disordersYang⁃tai GUANNeuromyelitis optica spectrum disorders (NMOSDs) have the characteristics of high relapse rate and high disability rate. The neurological deficits would become more and more serious with increasing relapse. Using corticosteroids pulse therapy, intravenous immunoglobulin or plasma exchange to reduce inflammation and inhibit neurological dysfunction is the main treatment principle of NMOSDs in the acute phase; drugs to prevent relapse of NMOSDs are mainly immunosuppressants, such as azathioprine, and targeted agents, such as CD19 monoclonal antibody, C5 complement, interleukin⁃6⁃receptor targeted antibodies and a proliferation⁃inducing ligand (APRIL)/transmembrance activator and calcium⁃modulator and cyclophilin ligand interactor (TACI) targeted therapy. Some targeted agents have been approved for clinical use. This article intended to review the targeted agents for NMOSDs patients for the purpose of improving the understanding of therapeutic strategies of NMOSDs. DOI: 10.3969/j.issn.1672-6731.2020.10.001http://www.cjcnn.org/index.php/cjcnn/article/view/2217neuromyelitis optica spectrum disorders (not in mesh)immunotherapyimmunosuppressive agentsreview |
| spellingShingle | Yang⁃tai GUAN Targeted therapy for neuromyelitis optica spectrum disorders Chinese Journal of Contemporary Neurology and Neurosurgery neuromyelitis optica spectrum disorders (not in mesh) immunotherapy immunosuppressive agents review |
| title | Targeted therapy for neuromyelitis optica spectrum disorders |
| title_full | Targeted therapy for neuromyelitis optica spectrum disorders |
| title_fullStr | Targeted therapy for neuromyelitis optica spectrum disorders |
| title_full_unstemmed | Targeted therapy for neuromyelitis optica spectrum disorders |
| title_short | Targeted therapy for neuromyelitis optica spectrum disorders |
| title_sort | targeted therapy for neuromyelitis optica spectrum disorders |
| topic | neuromyelitis optica spectrum disorders (not in mesh) immunotherapy immunosuppressive agents review |
| url | http://www.cjcnn.org/index.php/cjcnn/article/view/2217 |
| work_keys_str_mv | AT yangtaiguan targetedtherapyforneuromyelitisopticaspectrumdisorders |